# OrphoMed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/orphomed

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.orphomed.com
- Total disclosed funding: $22M
- Latest round: Series A (May 8, 2017)
- Investors on record: 6

## About

OrphoMed, Inc. is a healthcare technology company focused on developing advanced medical solutions that address critical challenges within the healthcare sector, enhancing patient outcomes through innovative diagnostic and therapeutic devices.Founded in 2015, OrphoMed, Inc. operates out of San Francisco, US. The company specializes in the creation of medical technologies and has secured a total of USD 21.77 mn through its Series A funding round on June 1, 2021, with investments from Latterell Venture Partners, Mario Family Partners, New Enterprise Associates, Pappas Capital, Relativity Healthcare Partners, and Takeda Ventures. The company is led by CEO Gary Phillips, while Nikhilesh Singh serves as the Founder.OrphoMed specializes in the development of advanced medical technologies aimed at addressing significant challenges in the healthcare sector. Their core product offerings include diagnostic solutions and therapeutic devices designed for use in a variety of clinical environments. These products are engineered to enhance patient outcomes by providing precise and timely data to healthcare professionals, thereby facilitating informed decision-making in treatment pathways. OrphoMed’s solutions primarily serve hospitals, clinics, and specialized medical facilities across various regions, including North America and Europe. The end users of their products encompass healthcare providers and patients, underscoring the company’s commitment to improving the quality of care through innovative technology.Revenue generation for OrphoMed is driven by a multifaceted approach, which includes direct sales of their proprietary medical devices to healthcare institutions and partnerships with larger healthcare organizations. The company’s transaction structure typically involves B2B agreements where hospitals and clinics procure devices through standardized contracts that may include service agreements for ongoing maintenance and support. Pricing plans are established based on the type of device and accompanying services offered, aligning with the company’s strategy to provide tailored solutions for various healthcare settings. OrphoMed's flagship products, recognized for their efficacy and reliability, contribute significantly to the overall revenue while reinforcing their position in the evolving healthcare market. The company’s focus on strategic partnerships further enhances its market reach and strengthens revenue streams.OrphoMed aims to expand its product line with upcoming diagnostic and therapeutic devices, although specific release dates have not been disclosed. The company is also targeting growth in new markets, specifically in Europe and Asia, with an anticipated entry by 2023. The recent funding of USD 21.77 mn from its Series A round will bolster these initiatives, supporting research and development efforts as well as market expansion strategies.

## Funding rounds

- Series A, May 8, 2017, $22M — Latterell Venture Partners, New Enterprise Associates, Pappas Capital, Takeda Ventures, Mario Family Partners, Relativity Healthcare Partners

## Investors

- Latterell Venture Partners (https://capitalatlas.ai/funds/latterell-venture-partners) — Series A
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A
- Pappas Capital (https://capitalatlas.ai/funds/pappas-capital) — Series A
- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series A
- Mario Family Partners — Series A
- Relativity Healthcare Partners (https://capitalatlas.ai/funds/relativity-healthcare-partners) — Series A